Dihydroergotamine
Acute treatment of migraine headaches, Acute treatment of cluster headache episodes
Boxed warning
- WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is ... (see full label)
Indications
- Acute treatment of migraine headaches
- Acute treatment of cluster headache episodes
Adult dosing
- acute migraine: dose: 1; unit: mL; route: IV - dihydroergotamine mesylate injection 1 mg/mL (1 mL ampule); interval: repeat at 1-hour intervals to a total of 2 mL in a 24-hour period; fixed: true; labelExcerpt: Dihydroergotamine Mesylate Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. The dose can be repeated, as needed, at 1-hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24-hour period.
- acute cluster headache: dose: 1; unit: mL; route: IM - dihydroergotamine mesylate injection 1 mg/mL (1 mL ampule); interval: repeat at 1-hour intervals to a total of 3 mL in a 24-hour period; fixed: true; labelExcerpt: Dihydroergotamine Mesylate Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. The dose can be repeated, as needed, at 1-hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24-hour period.
Pediatric dosing
- Consult pharmacy/current label
Renal adjustment
- Consult pharmacy/current label
Hepatic adjustment
- Contraindicated in patients with severely impaired hepatic function
Contraindications
- Potent CYP3A4 inhibitors
- Ischemic heart disease
- Uncontrolled hypertension
- Hemiplegic or basilar migraine
- Severely impaired hepatic or renal function
Clinical pearls
- Do not use for chronic daily administration.
- Monitor for peripheral ischemia and serious cardiac events.
- Do not use within 24 hours of 5-HT1 agonists or other ergot-type medications.
- Total weekly dosage should not exceed 6 mL.
Source and review
- DailyMed label (dihydroergotamine mesylate), Set ID b464a64d-b150-4f6b-b3df-e486a41294d7, effective 2026-05-26. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties